Product Description
Cediranib (AZD2171) is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, c-KIT, and platelet-derived growth factor receptors. Studies show cediranib to be generally well tolerated as monotherapy at doses of 45 mg/d or less.
Cediranib (AZD2171) is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, c-KIT, and platelet-derived growth factor receptors.
Biovision | 1613 | Cediranib (AZD2171) DataSheet
Alternate Name/Synonyms: AZD2171, Recentin
Appearance: Crystalline solid
Formulation: N/A
CAS Number: 288383-20-0
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: No
Molecular Formula: C₂₅H₂₇FN₄O₃
Molecular Weight: 450.51
Cell-Permeable?: Yes
Purity: ≥98%
Solubilities: DMSO (10 mM)
Handling: Protect from air and moisture
Country of Origin: USA
Tag Line: A VEGFR and c-Kit kinase inhibitor
MDL Number: MFCD09954115
PubChem CID: 9933475
SMILES: CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5
InChi: InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22 (31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H, 3-5,8-11H2,1-2H3
InChi Key: XXJWYDDUDKYVKI-UHFFFAOYSA-N